**Core Concept:** Buprenorphine is a partial agonist of opioid receptors. Opioid receptors are G-protein coupled receptors (GPCRs) that play a crucial role in the modulation of pain, reward, and stress response pathways. There are three main types of opioid receptors: mu (μ), delta (δ), and kappa (κ).

**Why the Correct Answer is Right:** Buprenorphine acts as a partial agonist at both mu (μ) and delta (δ) opioid receptors. This dual action contributes to its unique pharmacological profile, making it less prone to cause the unwanted side effects associated with full agonist opioids (e.g., respiratory depression, addiction risk, and tolerance). However, it does not bind strongly enough to kappa (κ) receptors to elicit kappa-receptor-mediated side effects such as euphoria, diarrhea, and itching.

**Why Each Wrong Option is Incorrect:**

A. **Option A (μ):** Buprenorphine has a lower affinity for mu receptors compared to full agonists like morphine. This partial agonism allows for reduced respiratory depression and addiction risk without compromising pain relief.

B. **Option B (δ):** Similarly to μ receptors, buprenorphine acts as a partial agonist at delta receptors, contributing to its favorable side effect profile.

C. **Option C (κ):** Buprenorphine does not selectively bind to kappa receptors, explaining why it does not cause kappa-mediated side effects.

D. **Option D (opioid receptor):** Buprenorphine is an opioid receptor agonist, which is correct, but the explanation provided for its side effect profile is incorrect.

**Clinical Pearl:** Understanding the pharmacology of buprenorphine helps in choosing appropriate pain management strategies for patients, especially in cases of opioid-induced withdrawal or tolerance. Additionally, it contributes to the broader knowledge of opioid receptor pharmacology.